Financial Status:
- Pro-forma cash and equivalents: $4.76 million as of December 31, 2023.
Q2 FY24 Achievements:
- Solid Tumor Strategy:
Manufacturing and Development:
- Signed an exclusive license with Sparx Group to develop a world-first CAR-iNKT cell therapy targeting Claudin 18.2 (CLDN18.2), expressed in gastric cancers (GC), gastroesophageal junction cancers (GEJC), and pancreatic cancer (PC).
Financial Strengthening:
- Completed GMP manufacturing and release of ALA-101 lentiviral vector for the lead CD-19-targeting iNKT cell product.
- Advanced manufacturing process development and scale-up.
Executive Appointment:
- Received a $1.92 million R&D Tax Incentive refund.
- Appointed Tim Luscombe as Chief Financial Officer (CFO) and Company Secretary.
Upcoming 12-Month Milestones:
- Proof-of-Concept Data:
Clinical Batches and IND Studies:
- Present initial proof-of-concept data for CLDN18.2-iNKT cells in H1 CY24.
Regulatory Approvals and Clinical Trials:
- Manufacture clinical batches of ALA-101 for phase I clinical trials (H1 CY24).
- Complete IND-enabling non-clinical safety and efficacy studies (H1 CY24).
Technology In-Licensing:
- Secure IND application with the FDA and/or regulatory filing with TGA for a phase I clinical trial in non-Hodgkin’s lymphoma (H2 CY24).
- Commence a phase I clinical trial in non-Hodgkin’s lymphoma (H2 CY24).
- In-license additional technologies to enhance the iNKT cell therapy platform.
Solid Tumor Targeting:
- Arovella's iNKT cell therapy platform aims to target solid tumors and has advantages over existing CAR-T treatments.
Specifics of iNKT Cells:
- Can be sourced from healthy donors without causing graft versus host disease (GvHD).
- Contain an invariant T cell receptor (iTCR) targeting lipid-bound CD1d on various tumor types.
- Can be modified to produce a chimeric antigen receptor (CAR) for dual-targeting of specific tumors.
- Can be expanded significantly from a single manufacturing batch.
- Exhibit natural efficacy against solid tumors, influencing the tumor microenvironment and targeting pro-tumor cells.
Novel Monoclonal Antibody (mAb) Sequence:
- Secured a global, exclusive license for a novel mAb sequence (SPX-101) targeting Claudin 18.2 (CLDN18.2) in cell therapies.
- SPX-101 has completed preclinical studies and is set for a phase I trial to treat gastric cancers.
Clinical Landscape:
- CLDN18.2 is a validated target, with products like zolbetuximab in clinical development. Zolbetuximab has Priority Review for treating GC and GEJC by the FDA, with an expected decision in 2024.
- Forums
- ASX - By Stock
- ALA
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-2
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add ALA (ASX) to my watchlist
|
|||||
Last
13.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $141.7M |
Open | High | Low | Value | Volume |
14.0¢ | 14.5¢ | 13.5¢ | $113.9K | 814.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 393710 | 13.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
14.0¢ | 3153 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 319636 | 0.135 |
14 | 472819 | 0.130 |
6 | 229992 | 0.125 |
16 | 491028 | 0.120 |
8 | 331696 | 0.115 |
Price($) | Vol. | No. |
---|---|---|
0.145 | 1723562 | 6 |
0.150 | 400007 | 6 |
0.155 | 684615 | 4 |
0.160 | 427411 | 4 |
0.165 | 265000 | 2 |
Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
Last
14.0¢ |
  |
Change
0.000 ( 3.70 %) |
|||
Open | High | Low | Volume | ||
14.0¢ | 14.5¢ | 13.5¢ | 234426 | ||
Last updated 15.51pm 14/06/2024 ? |
Featured News
ALA (ASX) Chart |